Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Arrowhead Pharmaceuticals revenue
Arrowhead Pharmaceuticals's revenue is $3.6 million.
What is Arrowhead Pharmaceuticals's revenue?
- Arrowhead Pharmaceuticals's revenue growth from 2011 to 2024 is 1,099.1%.
- Arrowhead Pharmaceuticals has 109 employees, and the revenue per employee ratio is $32,577.
- Arrowhead Pharmaceuticals's peak quarterly revenue was $151.8M in 2022(q2).
- Arrowhead Pharmaceuticals peak revenue was $243.2M in 2022.
- Arrowhead Pharmaceuticals annual revenue for 2023 was 240.7M, -1.03% growth from 2022.
- Arrowhead Pharmaceuticals annual revenue for 2024 was 3.6M, -98.52% growth from 2023.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
Arrowhead Pharmaceuticals historical revenue
Arrowhead Pharmaceuticals's peak revenue was $243.2M in 2022. The peak quarterly revenue was $151.8M in 2022(q2).
Arrowhead Pharmaceuticals's revenue increased from $296.1k in 2011 to $3.6M currently. That's a 1,099.1% change in annual revenue.
Arrowhead Pharmaceuticals annual revenue
Arrowhead Pharmaceuticals annual revenue over time
| Fiscal year / year | Arrowhead Pharmaceuticals revenue |
|---|---|
| 2011 | $296,139 |
| 2012 | $146,875 |
| 2013 | $290,266 |
| 2014 | $175,000 |
| 2015 | $382,000 |
| 2016 | $158,333 |
| 2017 | $31.4M |
| 2018 | $16.1M |
| 2019 | $168.8M |
| 2020 | $88.0M |
| 2021 | $138.3M |
| 2022 | $243.2M |
| 2023 | $240.7M |
| 2024 | $3.6M |
How accurately did Arrowhead Pharmaceuticals' revenue projections match actual performance?
Arrowhead Pharmaceuticals annual growth
Arrowhead Pharmaceuticals saw the greatest revenue growth in 2017, when revenue increased by 19,736.49%.
Arrowhead Pharmaceuticals had the lowest revenue growth in 2016, when revenue changed by -58.55%.
Arrowhead Pharmaceuticals annual growth rate over time
| Year | Arrowhead Pharmaceuticals growth |
|---|---|
| 2012 | -50%↓ |
| 2013 | 98%↑ |
| 2014 | -40%↓ |
| 2015 | 118%↑ |
| 2016 | -59%↓ |
| 2017 | 19736%↑ |
| 2018 | -49%↓ |
| 2019 | 946%↑ |
| 2020 | -48%↓ |
| 2021 | 57%↑ |
| 2022 | 76%↑ |
| 2023 | -1%↓ |
| 2024 | -99%↓ |
Arrowhead Pharmaceuticals quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Arrowhead Pharmaceuticals quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2012 | $23,958 | $31,250 | $47,917 | $43,750 |
| 2013 | $159,016 | $43,750 | $43,750 | $43,750 |
| 2014 | $43,750 | $43,750 | $43,750 | $43,750 |
| 2015 | $170,750 | $43,750 | $123,750 | $43,750 |
| 2016 | $43,750 | $43,750 | $39,583 | $31,250 |
| 2017 | $4.4M | $9.0M | $9.3M | $8.7M |
| 2018 | $3.5M | $650,125 | $727,375 | $11.3M |
| 2019 | $34.7M | $48.1M | $42.7M | $43.3M |
| 2020 | $29.5M | $23.5M | $27.4M | $7.6M |
| 2021 | $21.3M | $32.8M | $45.9M | $38.3M |
| 2022 | $27.4M | $151.8M | $32.4M | $31.6M |
| 2023 | $62.5M | $146.3M | $15.8M | $16.1M |
| 2024 | $3.6M | - | - | - |
| 2025 | $2.5M | - | - | - |
Arrowhead Pharmaceuticals jobs nearby
Do you work at Arrowhead Pharmaceuticals?
Did Arrowhead Pharmaceuticals meet its revenue projections?
Arrowhead Pharmaceuticals financial information
| CEO | Christopher Richard Anzalone |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 109 |
| Date Founded | 1989 |
| Headquarters | Pasadena, California |
| Number of Locations | 3 |
| Revenue | $3.6M |
| Net Income | -$205,275,000 |
| Gross Proft | ($16.2M) (2015) |
| PE Ratio | -2.29 |
| Tax Rate | 0.0% |
| Market Capitalization | $1.4B |
| Total Assets | $765,552,000 |
| Ticker | ARWR |
Arrowhead Pharmaceuticals jobs you might like
Arrowhead Pharmaceuticals financing
Arrowhead Pharmaceuticals received early financing of $10.0M on 2006-10-26.
| Series | Round size | Date |
|---|---|---|
| Post Ipo Equity | $10M | 10/2006 |
| Post Ipo Equity | $16.5M | 05/2007 |
| Post Ipo Equity | $2.8M | 08/2009 |
| Post Ipo Equity | $3.2M | 01/2010 |
| Post Ipo Equity | $36M | 05/2013 |
| Post Ipo Equity | $60M | 10/2013 |
| Post Ipo Equity | $45M | 08/2016 |
| Post Ipo Equity | $9.6M | 01/2017 |
| Post Ipo Equity | $266.8M | 12/2019 |
Arrowhead Pharmaceuticals investors
| Investors | Security type |
|---|---|
| York Capital Management | Post Ipo Equity |
| RA Capital Management | Post Ipo Equity |
| OrbiMed Advisors | Post Ipo Equity |
| Silence Therapeutics PLC | Post Ipo Equity |
Arrowhead Pharmaceuticals competitors
Arrowhead Pharmaceuticals's top competitor, Amyris, earned an annual revenue of $269.8M.
Arrowhead Pharmaceuticals's smallest competitor is Zyomyx with revenue of $840.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Zyomyx | - | $840,000 | 5 | - |
| Amyris | - | $269.8M | 595 | - |
| Morphotek | - | $4.8M | 1 | - |
| Celldex Therapeutics | - | $7.0M | 134 | - |
| NABsys Inc | - | $5.0M | 14 | - |
| Cytori Therapeutics | - | $7.4M | 12 | - |
| Renmatix | - | $15.0M | 48 | - |
Arrowhead Pharmaceuticals revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Arrowhead Pharmaceuticals highest paying jobs
Zippia gives an in-depth look into the details of Arrowhead Pharmaceuticals, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Arrowhead Pharmaceuticals. The employee data is based on information from people who have self-reported their past or current employments at Arrowhead Pharmaceuticals. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Arrowhead Pharmaceuticals. The data presented on this page does not represent the view of Arrowhead Pharmaceuticals and its employees or that of Zippia.
Arrowhead Pharmaceuticals may also be known as or be related to ARROWHEAD RESEARCH CORP, Arrowhead Pharmaceuticals, Arrowhead Pharmaceuticals Inc, Arrowhead Pharmaceuticals Inc. and Arrowhead Pharmaceuticals, Inc.